Danaher (NYSE:DHR) Price Target Cut to $277.00 by Analysts at Robert W. Baird

Danaher (NYSE:DHR) had its price target decreased by Robert W. Baird from $278.00 to $277.00 in a research report report published on Wednesday, Benzinga reports. Robert W. Baird currently has an outperform rating on the conglomerate’s stock.

DHR has been the subject of several other reports. TD Cowen raised their price objective on shares of Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a report on Wednesday, July 24th. StockNews.com cut Danaher from a “buy” rating to a “hold” rating in a research note on Tuesday, June 25th. Wells Fargo & Company started coverage on Danaher in a research note on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 price target on the stock. Barclays raised their price objective on Danaher from $270.00 to $285.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 24th. Finally, Leerink Partners upped their target price on shares of Danaher from $275.00 to $280.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Seven equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus price target of $287.28.

Danaher Trading Down 2.0 %

NYSE DHR opened at $256.00 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.04 and a current ratio of 1.43. Danaher has a fifty-two week low of $182.09 and a fifty-two week high of $281.70. The stock has a market cap of $189.62 billion, a P/E ratio of 43.39, a price-to-earnings-growth ratio of 4.49 and a beta of 0.83. The stock has a 50 day simple moving average of $270.43 and a two-hundred day simple moving average of $260.43.

Danaher (NYSE:DHR) last released its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same quarter in the previous year, the business posted $2.02 earnings per share. The firm’s revenue for the quarter was up 3.1% compared to the same quarter last year. On average, analysts forecast that Danaher will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be paid a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.42%. The ex-dividend date is Friday, September 27th. Danaher’s dividend payout ratio is currently 18.31%.

Insider Activity at Danaher

In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total value of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares of the company’s stock, valued at approximately $8,229,254.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Danaher news, CFO Matthew Mcgrew sold 16,172 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $8,229,254.88. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Rainer Blair sold 9,007 shares of the stock in a transaction on Wednesday, July 31st. The shares were sold at an average price of $280.00, for a total value of $2,521,960.00. Following the transaction, the chief executive officer now directly owns 97,983 shares in the company, valued at $27,435,240. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,059 shares of company stock valued at $8,400,897 over the last ninety days. Insiders own 11.10% of the company’s stock.

Institutional Investors Weigh In On Danaher

Hedge funds and other institutional investors have recently made changes to their positions in the business. AdvisorNet Financial Inc increased its holdings in Danaher by 11.3% during the first quarter. AdvisorNet Financial Inc now owns 758 shares of the conglomerate’s stock valued at $189,000 after buying an additional 77 shares during the last quarter. Dynamic Advisor Solutions LLC boosted its stake in shares of Danaher by 8.3% during the 1st quarter. Dynamic Advisor Solutions LLC now owns 7,744 shares of the conglomerate’s stock worth $1,934,000 after acquiring an additional 591 shares during the last quarter. Procyon Advisors LLC grew its position in shares of Danaher by 14.0% during the 1st quarter. Procyon Advisors LLC now owns 8,789 shares of the conglomerate’s stock valued at $2,195,000 after acquiring an additional 1,082 shares during the period. Wealth Enhancement Advisory Services LLC increased its stake in shares of Danaher by 3.8% in the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 194,515 shares of the conglomerate’s stock worth $48,574,000 after purchasing an additional 7,076 shares in the last quarter. Finally, Thrive Wealth Management LLC raised its holdings in Danaher by 4.9% in the 1st quarter. Thrive Wealth Management LLC now owns 6,070 shares of the conglomerate’s stock worth $1,516,000 after purchasing an additional 283 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.